2026-04-29T12:23:03Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/180432024-02-12T19:46:07Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16960col_20.500.12105_16963

00925njm 22002777a 4500 dc Cabrejos, Sheila author Moreira, Ana author Ramirez, Andreina author Quirce, Santiago author Soto Campos, Gregorio author Dávila, Ignacio author Campo, Paloma author 2020-05-06 A Spanish real-world study in patients with severe persistent asthma who achieved asthma control after a one-year treatment with omalizumab highlighted the phenotypic heterogeneity of these patients (FENOMA study). In this subanalysis, we describe the clinical improvement in patients with severe allergic asthma in this study (positive skin test and IgE level 30-1500 IU/mL); n=240. FENOMA was an observational, multicentre, retrospective study in 345 patients achieving asthma control according to Spanish guidelines (GEMA). Baseline demographic and asthma-related characteristics were collected. Outcomes analyzed were those included in asthma control definition plus changes in background treatments and in blood eosinophil count (%) and exhaled nitric oxide fraction [FeNO]. At baseline, patients were aged 45.4±15.0 years; 67% were women. Median (Q1;Q3) IgE levels were 302.5 (154.0; 553.5) IU/mL. After one-year treatment with omalizumab: 43.3% of patients had daytime symptoms vs 97.7% before treatment and 49.6% stopped taking oral corticosteroids. FEV1 increased a median of 12.0 (4.0; 23.0)%; P This study highlights the asthma control achieved by patients with severe allergic asthma treated with omalizumab, with relevant benefits on the burden of the disease both on patients and the healthcare system. 10.2147/JAA.S246902 1178-6965 Journal of asthma and allergy http://hdl.handle.net/10668/15615 32440161 http://hdl.handle.net/20.500.12105/18043 IgE Allergy Asthma Exacerbations Omalizumab FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma.